Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

Panelists discuss how the IMROZ trial demonstrated improved outcomes with quadruplet therapy combining daratumumab, lenalidomide, melphalan, and prednisone in patients with transplant-ineligible newly ...

The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.

Genmab A/S (NASDAQ:GMAB), a pharmaceutical company specializing in antibody therapeutics for cancer and maintaining an impressive 96.1% gross profit margin, has reported its net sales for DARZALEX® ...

Sanofi secures EU approval for Sarclisa with VRd for newly diagnosed multiple myeloma patients ineligible for stem cell ...

The phase 3 AURIGA study evaluated daratumumab (Darzalex) and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who were in very good partial response, minimal ...

The National Medical Products Administration or NMPA in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone or Pd to treat multiple myeloma or MM ...

an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior line of therapy ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients ...

赛诺菲今日宣布，旗下抗CD38单抗赛可益 ® （艾沙妥昔单抗注射液）获得国家药品监督管理局（NMPA）批准，用于与泊马度胺和地塞米松联合用药 ...